Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke "ACTION"

Completed

Phase 2 Results

Summary of Purpose

The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute ischemic stroke when given at ≤6 hours or at >6 to ≤9 hours from when they were last known normal (LKN). The secondary objectives of this study in this study population are as follows: to...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 24 May 2016.

1 Jan 2014 30 Sep 2013 1 Feb 2015 1 Apr 2015 1 May 2016 4 Feb 2016
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts